Fmr LLC Has $204.77 Million Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Fmr LLC trimmed its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 23.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,024,416 shares of the biopharmaceutical company’s stock after selling 1,804,748 shares during the quarter. Fmr LLC owned 9.08% of Celldex Therapeutics worth $204,770,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Point72 Asset Management L.P. increased its position in Celldex Therapeutics by 51.0% during the second quarter. Point72 Asset Management L.P. now owns 1,937,991 shares of the biopharmaceutical company’s stock worth $71,725,000 after acquiring an additional 654,194 shares during the period. Marshall Wace LLP grew its position in shares of Celldex Therapeutics by 53.3% during the 2nd quarter. Marshall Wace LLP now owns 1,377,868 shares of the biopharmaceutical company’s stock worth $50,995,000 after purchasing an additional 479,068 shares in the last quarter. Jennison Associates LLC raised its position in shares of Celldex Therapeutics by 32.0% in the third quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company’s stock valued at $45,017,000 after buying an additional 321,325 shares in the last quarter. Novo Holdings A S boosted its stake in shares of Celldex Therapeutics by 13.4% in the third quarter. Novo Holdings A S now owns 963,663 shares of the biopharmaceutical company’s stock valued at $32,755,000 after buying an additional 113,663 shares during the period. Finally, D. E. Shaw & Co. Inc. grew its position in Celldex Therapeutics by 47.5% during the second quarter. D. E. Shaw & Co. Inc. now owns 845,560 shares of the biopharmaceutical company’s stock worth $31,294,000 after buying an additional 272,389 shares in the last quarter.

Insider Transactions at Celldex Therapeutics

In other news, CEO Anthony S. Marucci bought 11,500 shares of the business’s stock in a transaction dated Monday, November 11th. The shares were purchased at an average price of $26.82 per share, for a total transaction of $308,430.00. Following the completion of the acquisition, the chief executive officer now owns 40,284 shares of the company’s stock, valued at approximately $1,080,416.88. This trade represents a 39.95 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 3.80% of the company’s stock.

Celldex Therapeutics Stock Down 0.8 %

Shares of CLDX stock opened at $27.23 on Tuesday. Celldex Therapeutics, Inc. has a 52 week low of $22.93 and a 52 week high of $53.18. The company has a market cap of $1.81 billion, a price-to-earnings ratio of -10.60 and a beta of 1.60. The firm has a 50 day moving average of $28.55 and a 200-day moving average of $34.30.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. The Goldman Sachs Group started coverage on Celldex Therapeutics in a report on Monday, September 30th. They issued a “neutral” rating and a $45.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research note on Monday, September 16th. Wells Fargo & Company upgraded shares of Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, September 26th. HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research report on Wednesday, November 20th. Finally, Citigroup initiated coverage on shares of Celldex Therapeutics in a research report on Monday, October 7th. They set a “buy” rating and a $70.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $62.25.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.